OpenAlex
PricingAboutJobs
Log inGet started
Work

Combination of the insulin sensitizer, pioglitazone, and the long‐acting GLP‐1 human analog, liraglutide, exerts potent synergistic glucose‐lowering efficacy in severely diabetic ZDF rats

HTML

Year: 2008
Type: article
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/j.1463-1326.2008.00865.x
Authors: P. J. Larsen, E. M. Wulff, C. F. Gotfredsen, C. L. Brand, J. Sturis, N. Vrang, L. B. Knudsen, K. Lykkegaard
Institution: Novo Nordisk (Denmark)
Language: English

Topic: Diabetes Treatment and Management
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: pioglitazone, liraglutide, combination therapy, type 2 diabetes, insulin resistance, beta-cell dysfunction, glucagon-like peptide-1 analogues, insulin sensitizers, glycemic control, HbA1c, oral glucose tolerance, dietary intake, body weight, Zucker diabetic fatty rats, antidiabetic drugs
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2171024875
FWCI: 1.955
Cites: 35
Cited by: 40
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security